MacroGenics, Inc.
9704 Medical Center Drive
Rockville, MD 20850
United States
301 251 5172
https://www.macrogenics.com
版塊: Healthcare
行業: Biotechnology
全職員工: 339
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Scott Koenig M.D., Ph.D. | President, CEO & Director | 1.2M | 無 | 1952 |
| Mr. James Karrels | Senior VP, CFO & Corporate Secretary | 693.31k | 無 | 1967 |
| Dr. Stephen L. Eck M.D., Ph.D. | Senior VP of Clinical Development & Chief Medical Officer | 766.85k | 無 | 1955 |
| Mr. Eric Blasius Risser | Chief Operating Officer | 651.36k | 無 | 1973 |
| Dr. Thomas M. Spitznagel Ph.D. | Senior Vice President of Technical Operations | 550.97k | 204.5k | 1967 |
| Dr. Ezio Bonvini M.D. | Senior VP of Research & Chief Scientific Officer | 612.21k | 264.03k | 1954 |
| Mr. Jeffrey Stuart Peters | Senior VP, General Counsel & Corporate Compliance Officer | 無 | 無 | 1971 |
| Ms. Lynn Cilinski | VP, Controller & Treasurer | 無 | 無 | 1958 |
描述
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
公司管治
截至 2024年4月1日 止，MacroGenics, Inc. 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：7；董事會：3；股東權利：7；現金賠償：5。
